Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis
-
By
-
Agni M. Konitsioti
-
Jeany Q. Lammert
-
Sabine Vay
-
Gereon R. Fink
-
Michael Schroeter
-
Clemens Warnke
-
April 29, 2026
-
Clinical Scorecard: Case Study: Ofatumumab-Induced Remission in Refractory Panuveitis Accompanied by Multiple Sclerosis
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | B-cell and T-cell mediated immune mechanisms contributing to disease pathogenesis. |
| Target Population | |
| Care Setting | |
Key Highlights
- Add highlight: Patient had a history of panuveitis and multiple treatments prior to ofatumumab.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Regularly assess visual function and uveitis activity.
- Monitor for side effects of immunosuppressive therapies, especially B-cell depleting agents.
Risks
Patient & Prescribing Data
Ofatumumab may be considered for patients who do not respond to conventional therapies, with attention to potential side effects.
Clinical Best Practices
- Consider a multidisciplinary approach involving neurology and ophthalmology, specifying roles in patient management.
References
